Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MACROGENICS INCMGNX · Entity 6104 | Chief Medical Officer | February 15, 2025 | February 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MACROGENICS INC
Report date February 15, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,377 |
Ending reported balance
After 2025-02-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-15 · Exercise / conversion · Acquired 16,665 · Balance 34,319 F1: On February 15, 2023, the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Row 2 · 2025-02-15 · Tax withholding · Disposed 4,942 · Balance 29,377 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,665 |
Reported balance
After 2025-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-15 · Exercise / conversion · Disposed 16,665 · Balance 16,665 F1: On February 15, 2023, the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 15, 2023, the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LUMINEX CORP
Report date July 14, 2021 · Filed July 15, 2021
Section 16 reporting ended · disclosed 2021-07-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,586 |
Reported balance
After 2021-07-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-14 · Disposition to issuer · Disposed 4,487 · Balance 33,586 F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share. F2: This total includes 266 dividend equivalent shares acquired from the Issuer as follows: 100 shares on 01/14/21, 77 shares on 04/15/21, and 89 shares on 07/08/21. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-07-14 · Disposition to issuer · Disposed 33,586 · Balance 0 F3: Disposed of pursuant to the Merger Agreement, whereby unvested restricted stock units ("Company RSUs") which were outstanding as of immediately prior to the Effective Time fully vested, and each Company RSU that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share.
F2: This total includes 266 dividend equivalent shares acquired from the Issuer as follows: 100 shares on 01/14/21, 77 shares on 04/15/21, and 89 shares on 07/08/21.
F3: Disposed of pursuant to the Merger Agreement, whereby unvested restricted stock units ("Company RSUs") which were outstanding as of immediately prior to the Effective Time fully vested, and each Company RSU that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2025 Filed Feb 19, 2025 21:20 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 16,665 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000029 · wk-form4_1740000037.xml · derivative · entry 3 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,665 Underlying: Common Stock · 16,665 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 15, 2023, the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 15, 2023, the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 15, 2023, the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:20 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 4,942 | $2.56 | $12,651.52 |
DisclosureSEC source: 0001125345-25-000029 · wk-form4_1740000037.xml · nonDerivative · entry 2 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,377 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:20 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 16,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000029 · wk-form4_1740000037.xml · nonDerivative · entry 1 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023, the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:34 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 11,168 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000020 · wk-form4_1739324076.xml · derivative · entry 5 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,332 Underlying: Common Stock · 11,168 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 8, 2024 the reporting person was granted 33,500 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 8, 2024 the reporting person was granted 33,500 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 8, 2024 the reporting person was granted 33,500 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:34 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 3,312 | $2.60 | $8,611.20 |
DisclosureSEC source: 0001125345-25-000020 · wk-form4_1739324076.xml · nonDerivative · entry 2 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,654 Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 01:34 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 11,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000020 · wk-form4_1739324076.xml · nonDerivative · entry 1 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 8, 2024 the reporting person was granted 33,500 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 01:34 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000020 · wk-form4_1739324076.xml · derivative · entry 4 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.exercise_price: On February 8, 2024 the reporting person was granted 33,500 restricted stock units, 33% of which vested on February 8, 2025 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F3 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 01:34 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 113,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001125345-25-000020 · wk-form4_1739324076.xml · derivative · entry 3 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 113,000 shares Expires 2035-02-07 F2 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:41 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 16,670 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000043 · wk-form4_1708472493.xml · derivative · entry 3 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,330 Underlying: Common Stock · 16,670 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 15, 2023 the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.exercise_date: On February 15, 2023 the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. F1 · derivative.expiration_date: On February 15, 2023 the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:41 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 6,872 | $17.40 | $119,572.80 |
DisclosureSEC source: 0001125345-24-000043 · wk-form4_1708472493.xml · nonDerivative · entry 2 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,798 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:41 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 16,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000043 · wk-form4_1708472493.xml · nonDerivative · entry 1 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 15, 2023 the reporting person was granted 50,000 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:31 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 33,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000017 · wk-form4_1707777058.xml · derivative · entry 2 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:31 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001125345-24-000017 · wk-form4_1707777058.xml · derivative · entry 1 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:27 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-23-000030 · wf-form4_167666919685342.xml · derivative · entry 2 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:27 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001125345-23-000030 · wf-form4_167666919685342.xml · derivative · entry 1 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 00:47 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $10.15 | $0.00 |
DisclosureSEC source: 0001125345-22-000027 · wf-form4_164575000344606.xml · derivative · entry 1 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 16:00 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerCommon Stock | 33,586 | $37.00 | $1,242,682.00 |
DisclosureSEC source: 0001033905-21-000058 · wf-form4_162637922357686.xml · nonDerivative · entry 2 Eck Stephen L. · CIK 0001669041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · shares: Disposed of pursuant to the Merger Agreement, whereby unvested restricted stock units ("Company RSUs") which were outstanding as of immediately prior to the Effective Time fully vested, and each Company RSU that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes). Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 16:00 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerCommon Stock | 4,487 | $37.00 | $166,019.00 |
DisclosureSEC source: 0001033905-21-000058 · wf-form4_162637922357686.xml · nonDerivative · entry 1 Eck Stephen L. · CIK 0001669041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,586 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share. F2 · balance_after: This total includes 266 dividend equivalent shares acquired from the Issuer as follows: 100 shares on 01/14/21, 77 shares on 04/15/21, and 89 shares on 07/08/21. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:02 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000024 · wf-form4_161420769525897.xml · derivative · entry 1 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 11:26 UTC | LUMINEX CORP LMNX · Entity 137318 | PurchaseCommon Stock | 450 | $22.40 | $10,081.94 |
DisclosureSEC source: 0001033905-20-000139 · wf-form4_160675357640624.xml · nonDerivative · entry 2 Eck Stephen L. · CIK 0001669041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,807 Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 11:26 UTC | LUMINEX CORP LMNX · Entity 137318 | PurchaseCommon Stock | 4,037 | $22.40 | $90,418.71 |
DisclosureSEC source: 0001033905-20-000139 · wf-form4_160675357640624.xml · nonDerivative · entry 1 Eck Stephen L. · CIK 0001669041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,357 F1 · balance_after: This total includes 109 dividend shares acquired on 10/15/20. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 11:49 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 799 | $0.00 | $0.00 |
DisclosureSEC source: 0001033905-20-000129 · wf-form4_160260417296808.xml · nonDerivative · entry 1 Eck Stephen L. · CIK 0001669041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,211 F1 · shares: Grant made pursuant to Luminex's Independent Director compensation policy for assuming the role of Strategy & Development Committee Chair. F2 · balance_after: This total includes 73 dividend shares acquired on 07/09/20. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:24 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 200,000 | $28.87 Strike: $28.87 | $5,774,000.00 |
DisclosureSEC source: 0001125345-20-000114 · wf-form4_159406705696583.xml · derivative · entry 1 Eck Stephen L. · CIK 0001669041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 15:29 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 4,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001033905-20-000063 · wf-form4_159112613588740.xml · nonDerivative · entry 1 Eck Stephen L. · CIK 0001669041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,339 F1 · balance_after: This total includes 303 dividend shares acquired as follows: 61 shares on 07/11/19, 93 shares on 10/17/19, 82 shares on 01/15/20, and 68 shares on 04/09/20. Read SEC document |
| May 17, 2019 Filed May 20, 2019 18:37 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 6,916 | $0.00 | $0.00 |
DisclosureSEC source: 0001033905-19-000048 · wf-form4_155839181712593.xml · nonDerivative · entry 1 Eck Stephen L. · CIK 0001669041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,333 F1 · balance_after: This total includes 138 dividend shares acquired as follows: 28 shares on 07/13/18, 33 shares on 10/12/18, 37 shares on 01/10/19, and 40 shares on 04/11/19. Read SEC document |
| May 17, 2018 Filed Jun 1, 2018 18:35 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 5,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001033905-18-000074 · wf-form4_152789251686616.xml · nonDerivative · entry 1 Eck Stephen L. · CIK 0001669041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,278 F1 · balance_after: This total includes 22 dividend shares from 07/14/17, 24 dividend shares from 10/13/17, 25 dividend from 01/12/18, 26 dividend shares from 04/13/18 and 5,567 shares from a new grant on 05/17/18. Read SEC document |
| May 18, 2017 Filed May 22, 2017 15:16 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 7,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001033905-17-000063 · wf-form4_149548054662507.xml · nonDerivative · entry 1 Eck Stephen L. · CIK 0001669041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,614 F1 · balance_after: This total includes 6 dividend shares from April 14,2017 payable date and 7,063 shares from a new grant on May 18, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.